In-Vivo Activated T-Cell Depletion to Prevent GVHD

NCT00594308 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped Treatment ineffective

Conditions

Acute Myelogenous Leukemia
Acute Lymphocytic Leukemia
Chronic Myelogenous Leukemia
Chronic Lymphocytic Leukemia
Myelodysplasia
Lymphoma, Non-Hodgkin's
Mantle-Cell Lymphoma
Hodgkin's Disease
Multiple Myeloma
Myelofibrosis

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Cyclosporine
DRUG: Mycophenolate mofetil
DRUG: Basiliximab

Sponsor

Indiana University